IRVINE, Calif.--(BUSINESS WIRE)--July 25, 2006--Cobalis Corp. (OTC BB: CLSC - News) a pharmaceutical development company focused on the treatment of allergy and other atopic conditions, announced today that it has enrolled its first patient into its twin Phase III Clinical Trials of its lead anti-allergy medication PreHistin(TM). The randomized, double blind, placebo-controlled studies are intended to assess the efficacy and safety of pre-seasonal treatment with PreHistin on moderate to moderately severe seasonal ragweed allergy patients.
